Well let’s see if they can produce on what Ken said in this statement on Sept 9th;
“Mr. Berlin continued, “We have continued our efforts to reduce cash burn and increase efficiencies, and with our improved cash position we will continue to focus our efforts on those programs most likely to improve patient outcomes and create shareholder value. We look forward to providing a more detailed pipeline update next month with important details relevant to the advancement of our innovative immunotherapy clinical programs”
Got to ask what are those important details, that will advance the clinical programs.
News 
Market Data 
Discover 
